Cemiplimab-rwlc has been approved by the FDA for non-small cell lung cancer with high PD-L1 expression

Share This Post

August 2021: The FDA approved cemiplimab-rwlc (Libtayo, Regeneron Pharmaceuticals, Inc.) for the first-line treatment of patients with advanced non-small cell lung cancer (NSCLC) (locally advanced who are not candidates for surgical resection or definitive chemoradiation or metastatic) whose tumours have high PD-L1 expression (Tumor Proportion Score [TPS] > 50 percent) whose tumours have high PD-L

Study 1624 (NCT03088540), a multicenter, randomised, open-label trial in 710 patients with locally advanced NSCLC who were not candidates for surgical resection or definitive chemoradiation, or with metastatic NSCLC, was conducted to assess efficacy. Patients were given either cemiplimab-rwlc 350 mg intravenously every 3 weeks for up to 108 weeks or platinum-based chemotherapy. Per a blinded independent central review, the major efficacy outcome measures were overall survival (OS) and progression-free survival (PFS) (BICR).

Patients who received cemiplimab-rwlc had statistically significant increases in OS and PFS when compared to those who received platinum-based chemotherapy. Patients in the cemiplimab-rwlc group had a median OS of 22.1 months (95 percent CI: 17.7, NE), compared to 14.3 months (95 percent CI: 11.7, 19.2) in the chemotherapy arm (HR 0.68; 95 percent CI: 0.53, 0.87, p=0.0022). The cemiplimab-rwlc arm had a median PFS of 6.2 months (4.5, 8.3) and the chemotherapy arm had a median PFS of 5.6 months (4.5, 6.1) (HR 0.59; 95 percent CI: 0.49, 0.72, p0.0001). In the cemiplimab-rwlc and chemotherapy groups, the confirmed overall response rate (ORR) per BICR was 37 percent (95 percent CI: 32, 42) and 21 percent (95 percent CI: 17, 25), respectively.

Musculoskeletal discomfort, rash, anaemia, exhaustion, decreased appetite, pneumonia, and cough were the most prevalent adverse events (> 10%) with cemiplimab-rlwc as a single drug in Study 1624.

The suggested dose of cemiplimab-rwlc for NSCLC treatment is 350 mg every three weeks, administered intravenously over 30 minutes.

Reference : https://www.fda.gov/

 

Check details here.

 

Take second opinion on non-small cell lung cancer treatment


Send Details

Subscribe To Our Newsletter

Get updates and never miss a blog from Cancerfax

More To Explore

Risk of developing secondary tumors following CAR-T cell therapy is minimal - A Stanford Study
CAR T-Cell therapy

Risk of developing secondary tumors following CAR-T cell therapy is minimal – A Stanford Study

CAR-T cell therapy, a groundbreaking cancer treatment, carries a risk of developing secondary tumors. This occurs due to the therapy’s potential to cause genetic mutations or alter the immune system’s regulation. Secondary malignancies can arise from these changes, presenting a significant long-term risk for patients. Continuous monitoring and research are crucial to understanding and mitigating these risks, ensuring safer outcomes for those undergoing CAR-T cell therapy.

Seattle Children's Hospital to Start CAR T-Cell Clinical Trial for Pediatric Lupus Patients
CAR T-Cell therapy

Seattle Children’s Hospital to Start CAR T-Cell Clinical Trial for Pediatric Lupus Patients

Seattle Children’s Hospital is launching a groundbreaking CAR T-cell clinical trial for pediatric lupus patients. This innovative approach harnesses the body’s immune cells to target and eliminate lupus-affected cells, offering new hope for young patients with this autoimmune disorder. The trial represents a significant advancement in lupus treatment, aiming to improve outcomes and reduce long-term complications for children suffering from this challenging condition.

Need help? Our team is ready to assist you.

We wish a speedy recovery of your dear and near one.

Start chat
We Are Online! Chat With Us!
Scan the code
Hello,

Welcome to CancerFax !

CancerFax is a pioneering platform dedicated to connecting individuals facing advanced-stage cancer with groundbreaking cell therapies like CAR T-Cell therapy, TIL therapy, and clinical trials worldwide.

Let us know what we can do for you.

1) Cancer treatment abroad?
2) CAR T-Cell therapy
3) Cancer vaccine
4) Online video consultation
5) Proton therapy